Boehringer Ingelheim Entered into a License Agreement with A*STAR to Develop and Commercialize Targeted Cancer Therapies Using Innovative Antibodies
Shots:
- A*STAR to receive $107.48M up front & success-based development & commercialization milestones. Boehringer Ingelheim will be responsible for the research, preclinical, clinical development & commercialization of targeted cancer therapies using Abs from A*STAR
- Boehringer to get exclusive rights globally to research, develop & commercialize products based on a tumor-specific Abs from A*STAR. EDDC showed the ability of the Abs to target cancer cells with different therapy approaches
- The collaboration allows Boehringer to strengthen its tumor cell-directed ADC & immune cell-targeted (T-cell engager) portfolio for highly targeted cancer treatments. A*STAR’s GIS & IBB generated Abs that target Ags found in gastric cancer cells
Ref: Businesswire | Image: Boehringer Ingelheim
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
